UBS analyst Danielle Antalffy downgraded Inspire Medical (INSP) to Neutral from Buy with a price target of $89, down from $230.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Nyxoah files patent infringement lawsuit against Inspire Medical
- Inspire Medical falls -9.1%
- Elf Beauty downgraded, Zscaler upgraded: Wall Street’s top analyst calls
- Inspire Medical initiated with an Outperform at Evercore ISI
- Inspire Medical Systems: Hold Rating Amid Leadership Transition and Stable FY25 Guidance